Drug intelligence / Profile preview

ferumoxtran-10

Development stage
Phase 3
Lead developer
SPL Medical
Modality
Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

Ferumoxtran-10 is a synthetic ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle coated with dextran. It functions as a molecular imaging agent for magnetic resonance imaging (MRI), primarily used to enhance the differentiation of cancerous from non-cancerous lymph nodes and to visualize phagocytic components in various tissues. The agent accumulates in the reticuloendothelial system and is taken up by macrophages in normal or reactive lymphatic tissue, leading to decreased signal intensity on T2-weighted MRI images. In contrast, metastatic lymph nodes lacking macrophages do not take up the agent and thus retain their original signal intensity. Ferumoxtran-10 can also cross areas of blood-brain barrier disruption and be trapped by phagocytic cells such as astrocytes and macrophages within or around tumors or lesions. It has been investigated for use in body imaging, oncologic staging (especially lymph node evaluation), and brain tumor imaging[1][2][4][5][6][7].

Brand names
Combidex
Other names
ultrasmall superparamagnetic iron oxideUSPIOdextran-coated iron oxide nanoparticles
02

Targets

MSR1 (Amyloid beta precursor protein binding family B member 3)

Beyond the preview

Go deeper on ferumoxtran-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ferumoxtran-10.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call